Clinical trial
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00023816 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00023816 |
|---|---|
| Title | Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma |
| Official title | Third Phase I and Pharmacokinetic Study Of FB-642 Administered Orally To Patients With Advanced Solid Tumors |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | carbendazim |
| First posted | Apr 5, 2004 |
| Last update posted | Sep 20, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: